ClinicalTrials.gg
RecruitingNCT07088458HEM-POWR KidsUpdated Nov 13, 2026

An Observational Study to Learn More About How Well Damoctocog Alfa Pegol Works in Children With Hemophilia A

An observational study in Hemophilia A, sponsored by Bayer. Recruiting at 12 sites in 11 countries. Open to participants aged 7 Years to 12 Years. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Bayer · Observational

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.
Updated Nov 13, 2026Now RecruitingFirst sites in 11 new countries+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
40
Ages
7 Years to 12 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 57 studies in Hemophilia A by Bayer — 3 open to participants now, 6 under way, none of them phase 3. Hemophilia A · Bayer.

Planned enrollment
18th of 26
40 · median 67
Started
2026
the only one that year
Observational
26 of 57
3 open now
Registered
56th of 57
by date

Among the 57 studies in Hemophilia A by Bayer, this one is the 18th largest by planned enrollment of the 26 observational ones that give a count, is the only one that started in 2026, is one of 26 observational ones, and was the 56th registered.

Hemophilia A

845 studies on the registry are indexed under Hemophilia A; 137 are open to participants now.

Browse Hemophilia A studies →

Who these studies take

Of the 88 Hemophilia A studies recruiting now, 52 (59%) set no upper age limit and 31 (35%) stop at 75 or younger; 56 take children under 18; 10 take healthy volunteers.

This study: 7 Years to 12 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies in Hemophilia A by Bayer, or all of them as a file.
02

Study summary

This is an observational study of children with mild, moderate, or severe hemophilia A who are receiving damoctocog alfa pegol, and are between 7 to \<12 years of age at the time of enrolment. Observational studies use data that are collected as part of routine medical care and participants do not receive any advice or any changes to healthcare as part of the study.

In this study, the data will be collected from participants who are starting or already receiving damoctocog alfa pegol as prescribed by their doctor. Participants taking part may have received factor 8 (FVIII) treatment before. The study may also include participants who have never received factor 8 treatment or who have received it only a few times.

Hemophilia A is a genetic bleeding disorder. It is caused by the lack of a protein called clotting factor 8 (FVIII) that helps blood to clot properly. Lack of FVIII can result in excessive blood loss or bleeding inside the body after being injured or having surgery. At times, there is spontaneous bleeding into the joint spaces that leads to joint damage.

The drug observed in this study, damoctocog alfa pegol, is approved for doctors to prescribe to children who are at least 7 years old with hemophilia A. It is used to prevent or treat bleeding episodes and works by replacing missing FVIII in the body of people with hemophilia A.

The participants will receive damoctocog alfa pegol as prescribed independently by their own doctors during routine practice, not as a part of the study. Participants may choose to enroll in the study at any time after their doctor has prescribed damoctocog alfa pegol to prevent bleeding episodes.

The main purpose of this study is to learn more about how a treatment with damoctocog alfa pegol works to prevent bleeding episodes in routine medical practice. To answer this question, doctors will collect:

  • information about bleeding episodes including the type and the location of the bleed
  • information about the treatment with damoctocog alfa pegol and other FVIII products
  • the overall health status of the participants

Data will be collected from participants over two years after they enroll in the study or until they choose to leave the study or switch to another hemophilia A treatment. Historical data will come from the participants' medical records or by interviewing the patient and parent/ legal guardian. The children's parents/ guardians will be asked to maintain a health diary to record details of bleeding episodes and treatment with damoctocog alfa pegol. The children's parents/ guardians will also be asked to answer a questionnaire (PedHAL) to assess the effect of hemophilia on their child's functional and physical activities.

In this study, only available data from routine care will be collected. No additional visits or tests are required as part of this study.

03

Conditions studied

  • Hemophilia A

Browse trials for

04

Who can participate

The criteria were revised on the registry on Nov 13, 2026. See what changed

Ages eligible
7 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients are to be enrolled from treatment centers specializing in the treatment of bleeding disorders in countries with market authorization for the use of damoctocog alfa pegol for patients aged ≥7 to \<12 years.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of hemophilia A
  • Patients must be 7 to \< 12 years of age at enrollment
  • Patients previously treated for hemophilia A (≥50 exposure days to FVIII) or in those countries with market authorization for the use of damactocog alfa pegol in all patients ≥7 years, patients previously not treated (previously untreated patients (PUPs) or minimally treated (≤4 exposure days (MTPs) with FVIII.
  • No current evidence of FVIII inhibitor or clinical suspicion of FVIII inhibitor
  • Patients without a previous history of inhibitors or patients with a previous history of inhibitors on standard prophylaxis therapy for at least 1 year prior to study entry
  • Initiation of prescription or currently prescribed damoctocog alfa pegol for regular continuous prophylaxis (intent to treat for 52 weeks/year)
  • Signed /assent.

Exclusion criteria

Exclusion Criteria:

  • Presence of a FVIII inhibitor
  • Concurrent participation in an program with interventions outside of routine clinical practice
  • Diagnosis of any other bleeding/coagulation disorder other than hemophilia A
  • Use of another hemostatic agent as the primary method of bleeding prophylaxis during the observation period
  • according to the local marketing authorization
  • Current immune tolerance induction (ITI) treatment for a FVIII inhibitor
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
40 participants (estimated)
Patient registry
No

Groups and cohorts

  • Previously treated patients (PTPs) with hemophilia A

    Previously treated patients with hemophilia A who have been prescribed damoctocog alfa pegol for regular continuous prophylaxis.

    Drug: Damoctocog alfa pegol (Jivi, Bay94-9027)

  • Previously untreated or minimally treated patients (PUPs/MTPs) with hemophilia A

    Patients previously not treated with FVIII (previously untreated patients (PUPs)), or minimally treated (≤4 exposure days (MTPs)).

    Drug: Damoctocog alfa pegol (Jivi, Bay94-9027)

Interventions

  • DrugDamoctocog alfa pegolStudies of Damoctocog alfa pegolDamoctocog alfa pegol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Follow clinical practice of BAY94-9027 to further define the treatment outcomes of damoctocog alfa pegol based on real-world use for regular prophylaxis in ages 7 to \<12 years, including a broader population and a real-world treatment patterns.

06

What researchers measure

Primary outcomes

  1. Number of treated bleeds per individual diary documentation period while prescribed damoctocog alfa pegol prophylaxis (overall and by dosing regimen)

    Time frame: Up to 24 months

Secondary outcomes

  1. Number of treated and all bleeds for the different bleed types (spontaneous, trauma, joint) per individual diary documentation period while prescribed damoctocog alfa pegol prophylaxis (overall and by dosing regimen)

    Time frame: Up to 24 months

  2. Occurrence of bleeds during individual diary documentation period while prescribed damoctocog alfa pegol prophylaxis prescription (overall and by dosing regimen)

    Time frame: Up to 24 months

  3. Occurrence of bleeds within 6 months' time intervals including the first and the last 6 months during observation period (overall and by dosing regimen)

    Time frame: Up to 24 months

  4. Presence of target joints at enrollment and at end of prophylaxis prescription (overall and by dosing regimen)

    Time frame: Up to 24 months

  5. Damoctocog alfa pegol dose per infusion (overall and by dosing regimen)

    Time frame: Up to 24 months

  6. Number of FVIII infusions (overall and by dosing regimen)

    Time frame: Up to 24 months

07

Study locations

1 of 12 sites recruiting
  • Loma Linda University Health
    Loma Linda, California 92354, United States
    Not yet recruiting
  • Rutgers, The State University
    New Brunswick, New Jersey 08901, United States
    Not yet recruiting
  • Many locations
    Many Locations, Brazil
    Not yet recruiting
  • Many locations
    Many Locations, Canada
    Withdrawn

    Not enrolling at this site.

  • Many locations
    Many Locations, Colombia
    Not yet recruiting
  • Many locations
    Many Locations, Denmark
    Not yet recruiting
  • Many locations
    Many Locations, Italy
    Not yet recruiting
  • Many locations
    Many Locations, Japan
    Not yet recruiting
  • Many locations
    Many Locations, Lithuania
    Recruiting
  • Many locations
    Many Locations, Mexico
    Not yet recruiting
  • Many locations
    Many Locations, Norway
    Not yet recruiting
  • Many locations
    Many Locations, Spain
    Not yet recruiting
08

References and documents

Individual participant data

Plan to share: No — Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Dec 2029, 41 months after the start.

Of 53 industry-sponsored observational studies under Hemophilia A, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 79. This study's planned 41 months is below that.

Counting every sponsor, half of 131 studies reached it within 45 months; a quarter within 25 and three quarters within 79.

Start moved once since we started tracking on Sep 25, 2026: Jun 2026 → Jul 2026, on Oct 26, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2025
First posted
Jul 28, 2025
StartActual
Jul 16, 2026was Jun 2026
Primary completionEst.
Dec 31, 2029
CompletionEst.
Mar 1, 2030
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 26, 2026
Sites
12 sites added — first sites in Brazil, Canada, Colombia, Denmark, Italy and 6 more
All 11 countries

Brazil, Canada, Colombia, Denmark, Italy, Japan, Lithuania, Mexico, Norway, Spain, United States

. Many locations is now Withdrawn
Show 12 added (2 United States, 1 Brazil, 1 Canada, 1 Colombia, 1 Denmark, 1 Italy, 1 Japan, 1 Lithuania, 1 Mexico, 1 Norway, 1 Spain)
  • Loma Linda University Health · Loma Linda, United States
  • Rutgers, The State University · New Brunswick, United States
  • Many locations · Many Locations, Brazil
  • Many locations · Many Locations, Canada
  • Many locations · Many Locations, Colombia
  • Many locations · Many Locations, Denmark
  • Many locations · Many Locations, Italy
  • Many locations · Many Locations, Japan
  • Many locations · Many Locations, Lithuania
  • Many locations · Many Locations, Mexico
  • Many locations · Many Locations, Norway
  • Many locations · Many Locations, Spain
across 2 updates, Oct 26, 2026 – Nov 13, 2026
Start date
Jun 30, 2026→Jul 16, 2026 (actual)
Oct 26, 2026
Eligibility
1 inclusion criterion edited
What changed in the criteria
Inclusion criteria
  • ChangedBefore Patients previously treated for hemophilia A ((≥50 exposure days to FVIII)Now Patients previously treated for hemophilia A (≥50 exposure days to FVIII) or in those countries with market authorization for the use of damactocog alfa pegol in all patients ≥7 years, patients previously not treated (previously untreated patients (PUPs) or minimally treated (≤4 exposure days (MTPs) with FVIII.
Nov 13, 2026
Interventions
Arms added: Previously untreated or minimally treated patients (PUPs/MTPs) with hemophilia A
Nov 13, 2026
Title
An Observational Study to Learn More About How Well Damoctocog Alfa Pegol Works in Previously Treated Children With Hemophilia A
Nov 13, 2026
Show all 2 updates
  1. Nov 13, 2026
    Many locations is now Withdrawn
    Eligibility 1 inclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • ChangedBefore Patients previously treated for hemophilia A ((≥50 exposure days to FVIII)Now Patients previously treated for hemophilia A (≥50 exposure days to FVIII) or in those countries with market authorization for the use of damactocog alfa pegol in all patients ≥7 years, patients previously not treated (previously untreated patients (PUPs) or minimally treated (≤4 exposure days (MTPs) with FVIII.
    Interventions Arms added: Previously untreated or minimally treated patients (PUPs/MTPs) with hemophilia A
    Title An Observational Study to Learn More About How Well Damoctocog Alfa Pegol Works in Previously Treated Children With Hemophilia A
    + 2 other changes: verification date and description
  2. Oct 26, 2026
    Not yet recruiting→Recruiting
    12 sites added — first sites in Brazil, Canada, Colombia, Denmark, Italy and 6 more
    All 11 countries

    Brazil, Canada, Colombia, Denmark, Italy, Japan, Lithuania, Mexico, Norway, Spain, United States

    Show 12 added (2 United States, 1 Brazil, 1 Canada, 1 Colombia, 1 Denmark, 1 Italy, 1 Japan, 1 Lithuania, 1 Mexico, 1 Norway, 1 Spain)
    • Loma Linda University Health · Loma Linda, United States
    • Rutgers, The State University · New Brunswick, United States
    • Many locations · Many Locations, Brazil
    • Many locations · Many Locations, Canada
    • Many locations · Many Locations, Colombia
    • Many locations · Many Locations, Denmark
    • Many locations · Many Locations, Italy
    • Many locations · Many Locations, Japan
    • Many locations · Many Locations, Lithuania
    • Many locations · Many Locations, Mexico
    • Many locations · Many Locations, Norway
    • Many locations · Many Locations, Spain
    Start date Jun 30, 2026→Jul 16, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07088458
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Jul 28, 2025
Start date
Jul 16, 2026
Primary completion
Dec 31, 2029 (estimated)
Completion
Mar 1, 2030 (estimated)
Last update
Nov 13, 2026

Study contacts

Bayer Clinical Trials Contact
Contact
clinical-trials-contact@bayer.com
(+)1-888-84 22937

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion